Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E13.84 EPS (ttm)6.52 Insider Own0.10% Shs Outstand714.26M Perf Week-1.88%
Market Cap64.43B Forward P/E7.23 EPS next Y12.47 Insider Trans-3.18% Shs Float703.78M Perf Month-7.80%
Income4.70B PEG0.83 EPS next Q2.64 Inst Own78.70% Short Float1.38% Perf Quarter-3.80%
Sales15.77B P/S4.09 EPS this Y4.80% Inst Trans0.10% Short Ratio2.08 Perf Half Y4.17%
Book/sh11.62 P/B7.76 EPS next Y16.26% ROA13.50% Target Price97.38 Perf Year5.15%
Cash/sh10.77 P/C8.38 EPS next 5Y16.60% ROE83.90% 52W Range58.59 - 98.97 Perf YTD40.74%
Dividend- P/FCF9.67 EPS past 5Y26.50% ROI16.50% 52W High-8.86% Beta1.46
Dividend %- Quick Ratio2.70 Sales past 5Y18.70% Gross Margin96.20% 52W Low53.95% ATR1.06
Employees8852 Current Ratio2.80 Sales Q/Q13.80% Oper. Margin42.40% RSI (14)28.83 Volatility0.89% 1.09%
OptionableYes Debt/Eq2.48 EPS Q/Q94.70% Profit Margin30.10% Rel Volume0.66 Prev Close90.91
ShortableYes LT Debt/Eq2.42 EarningsJul 25 BMO Payout0.00% Avg Volume4.64M Price90.20
Recom2.80 SMA20-3.34% SMA50-4.69% SMA2005.05% Volume3,082,139 Change-0.78%
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jul-20-19 09:53AM  The Week Ahead In Biotech: Pharma Earnings Pick Up Pace Benzinga
Jul-19-19 04:57PM  Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings? Zacks
01:59PM  FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçets Disease Business Wire
Jul-18-19 04:13PM  These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger Investor's Business Daily
10:33AM  Celgene (CELG) to Report Q2 Results: Wall Street Expects Earnings Growth Zacks
08:51AM  UnitedHealth (UNH) Beats on Q2 Earnings, Guides Up for 2019 Zacks
Jul-17-19 12:02PM  Congress set to vote on repeal of 'Cadillac tax' Yahoo Finance Video
10:10AM  Why Celgene (CELG) Could Beat Earnings Estimates Again Zacks
Jul-15-19 05:59PM  J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks
05:50PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
03:16AM  Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal Bloomberg
Jul-14-19 09:00AM  3 Incredibly Cheap Healthcare Stocks Motley Fool
Jul-13-19 12:18PM  3 U.S. Stocks to Watch in July Motley Fool
10:26AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
07:26AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-11-19 03:34PM  Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19? Zacks
03:00PM  4 Drug Stocks Getting Smashed InvestorPlace
11:16AM  FDA Accepts Sanofi's BLA for Myeloma Candidate to Review Zacks
Jul-10-19 01:54PM  Fred Hutch appoints execs from Amazon and Celgene to board American City Business Journals
08:41AM  Megadeals Enter Biotech Realm And 3 Other Trends To Watch In 2019 Investor's Business Daily
08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
Jul-09-19 05:50PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
08:00AM  Could $243 Billion In Extra Cash Be Coming Your Way Soon? Investor's Business Daily
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:00AM  3 Top Chinese Stocks to Watch in July Motley Fool
Jul-08-19 10:26AM  Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019 Motley Fool
Jul-05-19 08:57AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
08:35AM  Dow 30 Stock Roundup: Visa to Buy Verifi, Goldman May Launch Own Cryptocurrency Zacks
Jul-04-19 09:45AM  Karyopharm Gets Accelerated FDA Approval for Myeloma Drug Zacks
Jul-03-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
01:49PM  Why These 4 Biotech Leaders Could Rebound On Strong Earnings Investor's Business Daily
10:41AM  Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up Bloomberg
10:13AM  Will the Pharma Space Witness More Mega-Merger Deals in 2H? Zacks
Jul-01-19 06:12PM  Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer Zacks
09:25AM  Atara Reports Initial Data for Multiple Sclerosis Candidate Zacks
Jun-28-19 04:01PM  J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma Zacks
07:00AM  Almost $500 Billion of Megadeals Get Panned Instantly Bloomberg
Jun-26-19 05:40PM  The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far) Motley Fool
11:00AM  Big Pharma Has to Bet Big on M&A. Investors Dont. Bloomberg
11:00AM  AbbVie to Buy Allergan: Prescribed ETFs Zacks
09:26AM  AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal Zacks
09:22AM  The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene Zacks
Jun-25-19 04:15PM  AbbVie + Allergan: Where Are The Synergies? Zacks
03:56PM  Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down Zacks
01:30PM  Why politicians should not savage the $63 billion Abbvie-Allergan deal Yahoo Finance
11:02AM  The 10 Biggest Biotech Stocks Motley Fool
10:11AM  AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study Zacks
09:35AM  Company News For Jun 25, 2019 Zacks
Jun-24-19 08:06PM  Traders Still Avoiding Small Caps Investopedia -5.50%
04:55PM  What Happened in the Stock Market Today Motley Fool
04:29PM  US STOCKS-S&P 500 slips as healthcare drags, investors eye G20 summit Reuters
04:26PM  Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
04:23PM  Why These Innovative Biotech ETFs Soaring Zacks
04:14PM  Celgene Told To Divest Blockbuster Drug And Other Bad News For Bristol Investor's Business Daily
03:51PM  Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative Moody's
02:27PM  US STOCKS-Wall Street struggles for direction ahead of G20 summit Reuters
01:14PM  Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback Benzinga
01:12PM  US STOCKS-Wall St flat as healthcare losses limit tech gains Reuters
12:03PM  Bristol-Myers Will Divest Celgene Blockbuster to Close Deal Bloomberg
11:29AM  US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses Reuters
10:56AM  Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
10:54AM  Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
10:52AM  Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
10:39AM  US STOCKS-Wall Street edges higher as tech offsets healthcare loss Reuters
10:04AM  To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment American City Business Journals
09:00AM  Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed
08:14AM  UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal MarketWatch
07:45AM  Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
07:45AM  Bristol to divest Celgene's psoriasis treatment in FTC clearance push Reuters
07:43AM  UPDATE 2-Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
07:14AM  Bristol to divest Celgene's psoriasis treatment in FTC clearance push Reuters
06:59AM  Bristol-Myers Squibb Provides Update on Pending Merger with Celgene Business Wire
04:23AM  Stocks - Caesars Entertainment, Deere Rise Premarket; Spotify, Bristol-Myers Falls
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
09:15AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
08:53AM  5 Best-Performing S&P 500 Stocks So Far This Year Zacks
08:00AM  Where Will bluebird bio Be in 1 Year? Motley Fool
Jun-20-19 05:00PM  3 Drugs Under FDA Review With Blockbuster Potential Motley Fool
09:05AM  What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them? Motley Fool
Jun-19-19 04:07PM  Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH Zacks
12:02PM featured highlights include: Citigroup, DSW, Celgene and Zions Zacks
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
Jun-18-19 09:25AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
08:55AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 03:41PM  Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz Zacks
09:12AM  Regeneron (REGN) Presents Positive Data on Lymphoma Candidate Zacks
Jun-16-19 09:00AM  Is It Too Late to Buy Celgene Stock? Motley Fool
Jun-14-19 09:00AM  Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" PR Newswire
08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga
08:29AM  Mallinckrodt Presents Encouraging Data on Acthar Gel for RA Zacks
Jun-13-19 05:50PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
Jun-12-19 10:19AM featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:28AM  Boost Your Portfolio's Health With These 3 Big Drug Stocks Zacks
08:15AM  5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit Motley Fool
Jun-11-19 06:16PM  Insys Down on Bankruptcy News Amid Increasing Legal Expenses Zacks
12:09PM featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037502,209Jun 17 04:00 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
BARKER RICHARD WDirectorJun 15Option Exercise0.001,125013,673Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441041,861Jun 17 04:00 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375062,884Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037502,409Jun 17 04:00 PM
Haller Julia ADirectorJun 14Option Exercise0.0030002,034Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300062,509Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300039,420Jun 17 04:00 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0030001,834Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0048401,534Jun 17 04:00 PM
Friedman Michael ADirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 13Option Exercise0.00484039,120Jun 17 04:00 PM
MARIO ERNESTDirectorJun 13Option Exercise0.00484062,209Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
Haller Julia ADirectorJun 13Option Exercise0.0048401,734Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 03Option Exercise22.4724,666554,24524,666Jun 05 04:05 PM
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM